Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Anti-TIM-3 antibody MBG453 + hypomethylating agents for high-risk MDS & AML

Uma Borate • 8 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Antibodies Decitabine MBG453

Uma Borate, MD, Oregon Health & Science University, Portland, OR, discusses the use of MBG453, a monoclonal anti-TIM-3 antibody in combination with hypomethylating agents for high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients in a Phase Ib clinical trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Uma Borate

CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
Eric Padron et al. • 25 Mar 2024
1:21
Ruxolitinib plus venetoclax in heavily pretreated patients with R/R AML
Uma Borate • 8 Dec 2023
1:34
Impact of pre-treatment features & choice of therapy on outcomes of older adults with AML
Uma Borate • 8 Dec 2023
1:10
Canakinumab in preventing progression of high-risk CCUS to myeloid neoplasms: a Phase II study
Uma Borate • 8 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals